Publications

Spotlight Publication

Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)

Botensilimab plus balstilimab in an expanded cohort of 123 patients with metastatic microsatellite stable colorectal cancer and no active liver metastases

Jul 4, 2025

Schlechter, et al.

Filter by

More results...

Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)

Botensilimab plus balstilimab in an expanded cohort of 123 patients with metastatic microsatellite stable colorectal cancer and no active liver metastases

Jul 4, 2025

Schlechter, et al.

Botensilimab (Fc-Enhanced CTLA-4 Antagonist)

Monitoring botensilimab- and balstilimab-induced T cell dynamics in refractory mismatch repair proficient metastatic colorectal cancer

May 30

- Jun 3, 2025

Rasschaert et al.

Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)

Results from a phase 1 study of botensilimab and balstilimab in treatment refractory hepatocellular carcinoma

Apr 25

- Apr 30, 2025

El-Khoueiry, et al.

Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)

American Association for Cancer Research (AACR)

Apr 25

- Apr 30, 2025

Neoadjuvant botensilimab plus balstilimab in MMR proficient and deficient early-stage cancers: first results of the pan-cancer NEOASIS study

Chalabi et al.

Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)

American Association for Cancer Research (AACR) IO

Feb 23

- Feb 26, 2025

First-line Botensilimab and Balstilimab OPtimization in Microsatellite Stable COlorectal Cancer without liver, bone, or brain metastasis

DeVito et al.

Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)

American Association for Cancer Research (AACR) IO

Feb 24, 2025

Biomarker Analysis From a Phase II Study of AgenT-797 (invariant natural killer T cells) with Botensilimab (Fc-enhanced CTLA-4 inhibitor) and Balstilimab (anti-PD-1) in PD-1 Refractory Gastroesophageal Cancer

Cytryn et al.

Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)

American Association for Cancer Research (AACR) IO

Feb 24, 2025

Biomarker analysis from phase 2 study of agenT-797 (invariant natural killer T-cells), botensilimab (a Fc-enhanced CTLA-4 Inhibitor) with balstilimab (anti-PD-1) in PD-1 refractory gastroesophageal cancer (GEC)

Cytryn et al.

Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)

Journal of Clinical Oncology

Jan 27, 2025

Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti-PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas

Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)

American Society for Clinical Oncology (ASCO) GI

Jan 23

- Jan 25, 2025

Preliminary Results From a Randomized, Open-Label, Phase 2 Study of Botensilimab With or Without Balstilimab in Refractory Microsatellite Stable Metastatic Colorectal Cancer With No Liver Metastases

Fakih, et al.

Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)

American Society for Clinical Oncology (ASCO) GI

Jan 23

- Jan 25, 2025

A Phase I Trial of Folinic Acid, Fluorouracil, Oxaliplatin, Bevacizumab, Botensilimab, Balstilimab (FOLFOX-3B) in Microsatellite Stable Metastatic Colorectal Cancer

Fakih, et al.

Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)

American Society for Clinical Oncology (ASCO) GI

Jan 23

- Jan 25, 2025

Preoperative botensilimab (BOT) with or without balstilimab (BAL) for patients with resectable, locally advanced pMMR or dMMR colon cancer: results from the UNICORN trial by GONO

Ghelardi et al.

Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)

American Society for Clinical Oncology (ASCO) GI

Jan 23

- Jan 25, 2025

Neoadjuvant Botensilimab (BOT) Plus Balstilimab (BAL) in Resectable Mismatch Repair Proficient (pMMR) and Deficient (dMMR) Colorectal Cancer (CRC)

Hissong et al.